Drug safety evaluation of maraviroc for the treatment of HIV infection. - Wikidata - awgldk - TriplyDB

Drug safety evaluation of maraviroc for the treatment of HIV infection.

Drug safety evaluation of maraviroc for the treatment of HIV infection.

http://www.wikidata.org/entity/Q37961188

about

Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism.Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4 Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.Antiretroviral therapy: effects on orofacial health and health care.Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.CCR5 inhibition prevents cardiac dysfunction in the SIV/macaque model of HIV.Expert reviews: who are they for?

P2860

Q21559666-47280EBB-62EB-4808-94F5-C49B06C96250 Q33721466-8D6C6448-12FE-42FD-9FD4-F7743B3262E8 Q34400849-F404890F-B61A-4319-A7AD-7980A0E2F339 Q35029040-6D1D5C78-7423-4157-AA6B-2FBD3698F310 Q36698872-7AB50C79-2214-4BFC-910F-809B016897E8 Q36888917-D826815F-F757-4111-AFE7-4EE9FEA0FE74 Q37613476-213248AD-0F4A-4F9A-9836-78241B483E86 Q37637067-3EF724FC-69D6-4601-BD63-5923C831513C Q38093238-8BB9C223-317C-4B2E-BCB7-3D7B31327AA5 Q38970509-76A4445C-1065-4911-AFB8-E8FA6054426B Q42227332-56BED2FA-493A-45F5-B9C2-E4221BBEC923 Q49184404-CEE01985-111E-43EE-B711-98362A81EDF4

P2860

Drug safety evaluation of maraviroc for the treatment of HIV infection.

http://www.wikidata.org/entity/Q37961188

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@en

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@nl

type

label

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@en

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@nl

prefLabel

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@en

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@nl

P1433

Q37961188-BDEB16F3-7AD3-45E0-BECE-AEE9A36089E1

P1476

Q37961188-E14BA76E-3A75-495D-B637-83BFA9A829E9

P2093

Q37961188-0F8F957A-9642-484A-8F55-29A799BB16DD

Q37961188-7E1D1955-0B42-44B1-93CB-421F0FBD3FA4

Q37961188-A3091EBA-66B8-4B44-A9AB-564F2690197C

P2860

Q37961188-0171F0FE-A281-4D48-9578-D007D29CBD2B

Q37961188-0DB0E4EF-478F-489F-AF00-7F2E0BB1DB2C

Q37961188-10FC2D6D-E1BA-4E26-9137-9681FB87D14F

Q37961188-148E8EEE-514C-4A7B-9DDD-791C42B16FB7

Q37961188-1593DB3A-343A-4C2F-B9B2-C60BFDDD6FFD

Q37961188-159E7A3D-A982-4083-9E9C-80D5A9158FF6

Q37961188-1794F7AC-9E86-4DE4-99F2-773CE9868D10

Q37961188-1FFD7C84-C659-45E9-8620-DBED113B9AA4

Q37961188-266D90DA-C1E6-4C14-BE8D-9142B4D68724

Q37961188-287F370C-8080-4150-A423-2914A8845E6B

P304

Q37961188-1E445E7A-5C02-4063-9B1E-72AF55D2EF2F

P31

Q37961188-86A64906-145F-4854-B48E-86E90067B05E

P356

Q37961188-A98B5E94-C13A-4856-8FCC-FE63246BDF03

P407

Q37961188-F0844B4F-A0E5-4FB0-9D05-7FC81692B5D4

P433

Q37961188-B59153AB-0136-4DC5-A8DD-F248006BE5D2

P478

Q37961188-B364BB13-FF60-4110-9D30-0643EA033C07

P50

Q37961188-35C44445-6A4C-4B4A-A179-92F48BFF84B8

P577

Q37961188-7C030A0A-9A1C-4DD8-8400-694EE96EFC4C

P698

Q37961188-B1BE3208-EA47-4348-8B09-908E66E5DEF3

P921

Q37961188-BE71A540-71EA-4644-9597-8D36C99F655C

P356

14740338.2012.640670

P1433

Expert Opinion on Drug Safety

P1476

Drug safety evaluation of maraviroc for the treatment of HIV infection.

@en

P2093

Jan-Christian Wasmuth

http://www.w3.org/2001/XMLSchema#string

Jürgen Kurt Rockstroh

http://www.w3.org/2001/XMLSchema#string

William David Hardy

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

CCR5 deficiency increases risk of symptomatic West Nile virus infection

Raltegravir with optimized background therapy for resistant HIV-1 infection

A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

Interleukin-2 therapy in patients with HIV infection.

P304

161-174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2012.640670

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Jan-Christian Wasmuth

P577

2011-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22118500

http://www.w3.org/2001/XMLSchema#string

P921